|Bid||46.84 x 900|
|Ask||47.22 x 800|
|Day's Range||46.81 - 50.24|
|52 Week Range||42.69 - 99.00|
|Beta (5Y Monthly)||1.76|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||51.67|
SAN CLEMENTE, Calif., November 11, 2021--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today that its technologies will be highlighted in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held November 12–15, 2021 in New Orleans, Louisiana.
Despite reporting third-quarter loss, Glaukos' (GKOS) results reflect a significant rise in revenues.
Image source: The Motley Fool. Glaukos Corp (NYSE: GKOS)Q3 2021 Earnings CallNov 6, 2021, 2:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorWelcome to Glaukos Corporation's Third Quarter 2021 Financial Results Conference Call.